Protein metallocarboxypeptidase inhibitors (CPIs) are one of the less abundant inhibitors in nature. Only nine CPIs have been reported and can be divided in two groups according their inhibition mechanism: substrate like recognition or steric blockage of the active site. The first group is the most representative and includes CPIs that insert their C-terminal in the enzyme active site in a substrate feature, forming a stable complex. SmCI is a CPI isolated from the sea annelid Sabellastarte magnifica able to inhibit metallo CPA through a novel inhibition mechanism. It is a one-chain protein of 19703 Da, N-glycosilated and folded in three BPTI/Kunitz domains. The BPTI/Kunitz family represents typical serine protease inhibitors. However, SmCI is the only BPTI/Kunitz inhibitor able to additionally block CPA activity. In this work, we elucidated the inhibition mechanism of CPA by SmCI using kinetic and structural techniques. For the kinetic approach, we firstly obtained the recombinant SmCI bi-domains D1D2 and D2D3. Bi-domain D1D2 was the only one able to inhibit CPA. However, its 2-folds higher Ki value against this enzyme, compared with the natural and recombinant tri-domain forms (SmCI and SmCIr), indicates its lower inhibition strength. This kinetic data suggests that the first domain has the essential role in CPA inhibition, but also, the requirements of the whole tri-domain molecule to reach the maximal inhibition. The interaction mechanism was later detailed from the crystallographic structure of the SmCI-CPA complex. For better results during the crystallization trials, we firstly obtained and characterized the non-glicosilated mutant SmCI N23A. The SmCI N23A-humanCPA4 complex structure was obtained by X ray crystallography (2.2Å resolution) and it surprisingly revealed the N-terminal tail of SmCI inserted in the enzyme active site. These results represents the first non-canonical mechanism described for metallo CPA enzymes. SmCI N-tail is able to keep the same kind of interactions in the primary site compared to inhibitors with a substrate-like mechanism. Interestingly, P1-P2-P3 positions (the three residues inserted in the active site) in both kinds of inhibitors share a similar backbone and side chain orientation. They are only different in the capability to chelate the Zn2+ atom present in the enzyme active site. CPIs with a substrate-like interaction mechanism chelate Zn2+ atom with the carboxylate terminal group, excluding catalytic water from its functional position. In contrast, SmCI N-terminal indirectly contacts the Zn2+ atom by the water molecule. The latter, even in its functional position loses its catalytic properties when the SmCI-CPA complex is formed. This work describes a novel non-canonical interaction mechanism for CPA enzymes but also the first 3D structure of a BPTI/Kunitz protein formed by three domains. Our results contribute to current basic biochemical knowledge in the CPA-inhibitor structure-function relationship. We support a new potential structural motive capable to inhibit CPA, which also represents a starting point in the design and development of biomedical and biotechnological applications of SmCI or new synthetic inhibitors. In addition, SmCI domain architecture suggests the possibility of a simultaneous inhibition of metallo CPA and serine proteases by different primary sites found in the inhibitor for the binding of each enzyme catalytic type. This feature could suggest a possible SmCI role as a defense mechanism against S. magnifica predators.
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